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ABSTRACT Activation of the endothelin receptor B
(ETRB) in cultured melanocyte precursors promotes cell
proliferation while inhibiting differentiation, two hallmarks of
malignant transformation. We therefore tested whether ETRB
has a similar role in malignant transformation of melanoma.
When tested in culture, we find that the selective ETRB
antagonist BQ788 can inhibit the growth of seven human
melanoma cell lines, but not a human kidney cell line. This
inhibition often is associated with increases in pigmentation
and in the dendritic shape that is characteristic of mature
melanocytes. In three cell lines we also observe a major
increase in cell death. In contrast, the endothelin receptor A
(ETRA) antagonist BQ123 does not have these effects, al-
though all the cell lines express both ETRA and ETRB mRNA.
Extending these studies in vivo, we find that administration of
BQ788 significantly slows human melanoma tumor growth in
nude mice, including a complete growth arrest in half of the
mice treated systemically. Histological examination of tumor
sections suggests that BQ788 also enhances melanoma cell
death in vivo. Thus, ETRB inhibitors may be beneficial for the
treatment of melanoma.
Cells in the early embryo and cells in advanced stages of
malignant transformation can share common features such as
a high rate of proliferation andyor lack of contact inhibition
and a low degree of differentiation. In the case of melanocytes,
the c-kit receptor and its ligand Steel are active at a relatively
advanced stage in melanocyte precursor development and are
essential for the survival and differentiation of these cells (1,
2). The function of these signaling molecules is lost gradually
during melanoma transformation, and enforced c-kit expres-
sion can induce melanoma cells to differentiate (3). Similarly,
other growth factors and receptors that are involved in normal
melanocyte development (4) are thought to play a similar role
in melanoma transformation (5).
Human melanocyte precursors fail to develop properly in
individuals with mutations in the gene encoding endothelin
receptor B (ETRB), a syndrome known as Hirschsprung’s
disease (6). Similarly, mice develop pigmentation abnormali-
ties (spotting) when either ETRB or its ligand endothelin 3
(ET3) do not function during embryonic development (7, 8).
In culture, ET3 enhances the proliferation and delays the
differentiation of melanocyte precursors (9, 10), an effect
correlated with increased expression of ETRB (11). Such
findings led us to hypothesize that ETRB also could be
involved in melanoma growth. Indeed, all human melanoma
lines tested so far express ETRB (12–15), and expression is
correlated with their differentiation state. Increased ETRA
expression, in contrast, is associated with induced differenti-
ation of A375 melanoma cells, whereas ETRB is expressed
predominantly in the malignant state (14). Although one
report indicates that ET1, acting through ETRB, mediates
mitogenic and chemokinetic effects on cultured melanoma
cells (12), another report suggests that the same ligand–
receptor system slows growth and induces apoptosis when
A375 cells are synchronized (16). Because the specific ETRB
inhibitor BQ788, a modified peptide (17), antagonizes effects
of ET3 on melanocyte precursors by reducing proliferation and
increasing pigmentation (R.L., unpublished data), we tested
this inhibitor on human melanoma cell growth in culture and
in an in vivo tumor model in nude mice.
MATERIALS AND METHODS
Cell Culture. Human melanoma cell lines were obtained
from the American Tissue Culture Collection (ATCC) and
were cultured with DMEM (ATCC) containing 10% FCS
(Gemini Biological Products, Calabasas, CA), 2 mM glutamine
(GIBCOyBRL), and 100 mgyml antibiotics (Pen-Strep mix;
GIBCOyBRL) in a humidified incubator with 5% CO2 at 37°C.
BQ788 and BQ123 (Calbiochem) were dissolved in 2%
polyoxythylene (60)-hydrogenated castor oil (HCO60; Nikko
Chemicals, Tokyo). Cells were cultured in 96-well ELISA
plates (Falcon). For the cell viabilityycell number assay, the
day after plating, inhibitor or vehicle was added and the
cultures were incubated for 4 days. The MTS assay [3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] was used to quantify
cells by measuring OD at 492 nm (Promega). P values were
calculated by using the Student’s t test for absolute values.
Reverse Transcription–PCR Analysis. Total RNA was iso-
lated from each cell line by using an RNA isolation kit
(Promega). The cDNA was prepared from 10 mg total RNA
using MMLV Reverse Transcriptase (GIBCOyBRL). Two
micrograms of cDNA was used for each PCR. Primers and
conditions were as described previously (18).
Immunohistochemistry. Tumors were frozen on dry ice, cut
into 20-mm sections on a cryostat, and stored at 280°C.
Sections were rinsed in calcium- and magnesium-free PBS,
fixed in 4% paraformaldehyde for 1 hr at room temperature,
blocked with 2% rabbit serum, and incubated with primary
antibody overnight at 4°C. After washing in PBS, sections were
incubated with a biotinylated secondary antibody, and staining
was developed by using the Elite ABC kit (Vector Laborato-
ries). The primary antibody used in this study was a monoclo-
nal rat anti-mouse CD31 (platelet endothelial cell adhesion
molecule). The terminal deoxynucleotidyltransferase-
mediated UTP end labeling (TUNEL) staining kit was ob-
tained from Boehringer Mannheim.
RESULTS
BQ788 Induces Signs of Differentiation and Reduces the
Viability of Human Melanoma Cells in Vitro. To test the
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hypothesis that ETRB function plays a role in melanoma cell
growth and differentiation, we cultured seven human mela-
noma cell lines and a human kidney cell line with the highly
selective ETRB antagonist BQ788 (17) (Novabiochem; N-cis-
2,6-dimethylpiperidinocarbonyl-L-g-MeLeu-D-TRP(MEOCO)-
D-Nle-OH, sodium salt). Concentrations up to 100 mM were
tested, because this was the highest dose at which strong
specificity of the compound for ETRB was demonstrated
previously (17). Inspection of the treated cultures reveals
drastic morphological changes in some of the melanoma lines.
As shown in Fig. 1 A and B, SK-MEL 28 cells develop large
cytoplasmic vacuoles and enhanced pigmentation. Similar
changes are seen with antagonist treatment of A375 and RPMI
7951 cells (not shown). All cell lines flatten significantly on the
dish surface, and most (except SK-MEL 3) show major in-
creases in pigmentation (Fig. 1). Treatment of SK-MEL 5 cells
also results in a dendritic phenotype similar to that observed
in normal, mature melanocytes (Fig. 1 C and D). In contrast,
treatment of kidney 293 cells with BQ788 does not result in any
morphological change (data not shown), demonstrating that
this inhibitor does not cause such effects in all cell types.
In addition to inducing morphological changes indicative of
differentiation, treatment of the melanoma cells with BQ788
eventually results in reduced cell number and cell death. This
effect was quantified by using the MTS assay. As shown in Fig.
2, all seven melanoma lines show a significant loss in the
number of viable cells upon treatment with 100 mM BQ788,
although some lines are more sensitive than others. In contrast,
the number of kidney cells is increased somewhat by high
concentrations of BQ788, demonstrating that this inhibitor is
not generally toxic.
To estimate how much of the decrease in viable melanoma
cells is due to cell death, we evaluated the percentage of dying
cells in drug-treated and control cultures. The results summa-
rized in Table 1 show that some of the melanoma lines display
a striking increase in TUNEL labeling with BQ788 treatment
(13- to 40-fold more than controls). In contrast, other lines
display no significant increase in TUNEL labeling, suggesting
that the effect of BQ788 on these lines is primarily through
inhibition of proliferation.
To verify that the cells express ETRB, we performed reverse
transcription–PCR by using published primer sequences (18).
All of these cell lines, including the kidney cells, display a band
of the size expected for authentic ETRB mRNA (Fig. 3A). Five
additional PCR cycles were required to detect this band in
RPMI 7951 cells. In addition, all cell lines express ETRA (Fig.
3B). Similar findings on receptor expression in some of these
lines have been reported previously (12, 14).
The coexpression of ETRA allowed us to examine the effect
of adding the selective ETRA antagonist BQ123 (19) to these
cells. As shown in Fig. 4, BQ123 does not reduce the number
of viable cells in any of the cell lines, even at high concentra-
tion. In fact, this antagonist slightly increases cell number in
two of the melanoma lines, A375 and SK-MEL 28. Thus, the
effects of BQ788 at high concentration are not mediated
through ETRA.
To examine further the effect of BQ788, we used the highly
selective ETRB agonist, sarafotoxin 6c (S6c) (20). As pre-
dicted, at concentrations of 0.1–1 mM, S6c increases A375 cell
number (Fig. 5). Importantly for the present experiments, S6c
completely blocks the effects of BQ788 on A375 cells (Fig. 5).
Thus, the ability of BQ788 to lower melanoma cell number is
likely to be through its action on ETRB and not as a side effect
on another aspect of melanoma cell physiology.
These results provide the first indication that an ETRB
antagonist can impair melanoma cell viability in culture and
suggest the possibility of using such drugs to inhibit the growth
of melanoma tumors in vivo.
BQ788 Inhibits Human Melanoma Growth in Nude Mice.
For the in vivo experiments we chose the A375 melanoma cell
Table 1. Treatment with BQ788 increases TUNEL staining in
certain melanoma cell lines in culture
Cell line BQ788 Control Dx
RPMI 7951 76.4 6 6.1 1.9 6 1.1 40.2*
SK MEL 28 7.4 6 1.6 0.4 6 0.3 18.5*
A375 21.6 6 5.4 1.6 6 0.1 13.5*
SK MEL 5 1.5 6 1.3 0.5 6 0.2 3
SK MEL 24 1.2 6 0.5 0.6 6 0.2 2
SK MEL 31 7.8 6 1.6 3.5 6 1.2 2.2
SK MEL 3 1.4 6 0.4 1.7 6 1.1 0.8
Kidney 293 2.8 6 1.3 3.4 6 0.2 0.8
TUNEL staining is expressed as percent positive cells after 4 days
in culture in the presence of 100 mM BQ788 and compared with
vehicle-treated cells as the control. Dx represents the fold increase; *P
, 0.05. P for percent values was calculated by using the Mann–Whitney
test (n 5 3–5).
FIG. 1. The ETRB antagonist BQ788 induces morphological
changes in cultured melanoma cells. Cells were cultured for 4 days with
100 mM BQ788 (A and C) or with vehicle (B and D). The cell lines were
melanoma line SK-MEL 28 (A and B) and melanoma line SK-MEL 5
(C and D). Note the different shape of the drug-treated melanoma
cells and their accumulation of black pigment. Pictures were taken with
bright-field optics at 340 magnification.
FIG. 2. BQ788 reduces the number of viable cells in cultured
melanoma but not kidney cells. Cells were cultured in the presence of
the antagonist, vehicle, or with no treatment for 4 days. Three wells of
each condition were subjected to the MTS assay. The mean values were
calculated and plotted as the percentage of the vehicle-treated value 6
SEM. The experiment was repeated three times, with similar results.
BQ788 values are indicated by p when significantly different from
controls (P , 0.05).
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line. Although this line is not the most sensitive to BQ788
treatment in culture, it is known to grow readily in nude mice.
First, dissociated cells were injected as a suspension into the
flanks of nude mice. When tumors developed, they were
excised, cut into pieces of approximately 3 mm in diameter, and
implanted under the skin of a new series of nude mice. When
a tumor reached 4 mm in diameter (which takes approximately
12 days), 25 ml of a solution containing 20 mgyml BQ788
dissolved in 2% HCO60 (17) was injected into the tumor daily
for 9 days. This dose was chosen based on a clinical trial by
Haynes et al. (22), who studied the effect of a nonselective ETR
antagonist on blood pressure in healthy volunteers, where no
significant side effects were observed. In this trial the highest
dose was of 1000 mg, which we estimate would correspond
approximately to a dose of 0.5 mgymouse. Tumors in control
mice were injected in the same way, with 25 ml of 2% HCO60.
Before each injection the tumor dimensions were measured
with calipers. Tumor volume was calculated as length 3 width2
3 0.5. Results from three experiments, using a total of 10
BQ788-treated mice and 8 vehicle-treated mice, are shown in
Fig. 6. At the outset, the mean tumor volume was 26 mm3 in
both control and BQ788-treated mice. After 9 days the mean
tumor volume of the control group reached 376 mm3 whereas
the BQ788-treated group had a mean tumor volume of 84 mm3.
Calculation of the growth rate (final size minus initial sizey
time) reveals that the BQ788-treated tumors grow six times
slower than control tumors. Similar conclusions come from
comparison of tumor weights (means of 446 mg vs. 93 mg; P ,
0.005).
Although these results encourage the idea that ETRB
inhibitors may prove useful in controlling melanoma growth in
vivo, intratumor drug delivery is not the most clinically relevant
approach if tumors have spread. Therefore, we asked whether
systemic administration of BQ788 also inhibits tumor growth.
In these experiments, tumor induction and the starting point
of the treatments were as for the intratumor experiments. At
FIG. 3. Reverse transcription–PCR reveals the expression of
ETRB and ETRA mRNA in all cell lines used. Bands corresponding
to ETRB (A) (220 bp) and ETRA (B) (352 bp) mRNAs were obtained
by using published primer sequences and protocols (18). For the cell
line RPMI 7951, an additional five PCR cycles were needed to obtain
a strong band for the ETRB shown in A. Molecular weight markers (m)
are shown in the outer lanes of the gel near the negative controls, in
which the cDNA was omitted.
FIG. 4. The selective ETRA antagonist BQ123 does not reduce the
number of viable melanoma cells in culture. Conditions and presen-
tation are as described for the BQ788 experiment shown in Fig. 2.
FIG. 6. Intratumor injection of BQ788 inhibits melanoma tumor
growth in nude mice. Nude mice (nuynu, BALByc background) were
implanted with grafts of A375 cells s.c. in the flank. After the tumors
had reached approximately 4 mm in diameter they were injected daily
with BQ788 for 9 days. Perpendicular tumor diameters were measured
daily to estimate tumor volume. Controls were injected on the same
schedule with vehicle. Data from three experiments using 10 BQ788-
treated mice and 8 vehicle-treated mice are pooled. P values were
calculated by using the Student’s t test and are indicated by p when
significantly different from controls (P , 0.05). Similar conclusions
come from measuring tumor weights, as described in the text.
FIG. 5. An ETRB-selective agonist abrogates the effects of BQ788
on melanoma cells. In experiments similar to those illustrated in Fig.
2, S6c (0.1–25 mM) was tested for its effects on A375 cells cultured for
4 days alone or in combination with BQ788 (75 mM). The ETRB
agonist stimulates cell growth and blocks the inhibitory effect of the
ETRB antagonist. The means of absolute values (n 5 3–5) were
calculated 6 SEM and plotted. P values were calculated by using the
Student’s t test and are indicated by p when significantly different (P ,
0.05) from controls or in comparison with BQ788 values when the
addition of S6c to BQ788 was tested.
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that point, mice were injected with 100 ml of BQ788 solution
(0.6 mg of BQ788 in 30% water and 70% saline, at a final
HCO60 concentration of 0.6%) i.p. once or twice a day for a
period of 9 days. Control mice received the same injections but
without BQ788. In the first experiment, mice were injected
once a day, and in the second experiment, the mice were
injected in the morning and then again in the early evening.
Because results from these two experiments did not differ, they
were pooled and are presented in Fig. 7A. It is clear that
systemic administration also results in effective inhibition of
tumor growth. This graph, however, does mask an important
heterogeneity in the response of the mice to BQ788. For the
first 6 days, tumors in the BQ788 group did not differ
significantly from their size at day 1. After 6 days, the BQ788
mice could be divided into two subgroups that responded
differently to the drug, as shown in Fig. 7B. In one set of mice,
BQ788 treatment slows tumor growth whereas in the other set
of mice, the tumors shrink and display complete growth arrest.
Several of the tumors from the i.p. injection experiment
were taken for histological examination on day 10. Sections
were stained with anti-CD31 antibody for angiogenesis and
with the TUNEL method for apoptosis. In general, BQ-788
treatment results in enhanced TUNEL labeling (Fig. 8),
suggesting that the drug increases melanoma cell apoptosis in
vivo as well as in culture. Staining with the anti-CD-31 antibody
to highlight blood vessels provided no evidence that BQ788
blocks angiogenesis (data not shown).
DISCUSSION
These results demonstrate that the ETRB inhibitor BQ788 is
an effective agent for slowing or, in some cases, completely
stopping human melanoma tumor growth in the nude mouse
model. Although the mechanism of this effect is not yet clear,
our culture experiments suggest that BQ788 slows melanoma
cell growth, induces differentiation, and eventually causes
cell death. The heterogeneity in the response of these
melanoma lines to this inhibitor supports a model of pro-
gressive effects. The lines least affected by BQ788 (SK-MEL
3, 24, and 31) display f lattening on the dish surface, a
significantly slowed growth rate, and (except for SK-MEL 3)
increased pigmentation. The SK-MEL 5 line displays similar
responses, but also shows increased dendritic morphology
characteristic of differentiated melanocytes. The lines most
sensitive to BQ788 (A375, SK-MEL 28, and RPMI 7951)
have, in addition, cytoplasmic vacuoles and an almost com-
plete loss of viability accompanied by a significant increase
in TUNEL staining, which is suggestive of apoptosis.
These effects appear to be mediated specifically by the
action of BQ788 on ETRB itself because the drug is inef-
fective on A375 cells in the presence of the ETRB agonist
FIG. 7. Systemic administration of BQ788 inhibits melanoma
tumor growth in nude mice. The experiments were similar to those
described in Fig. 6, except that the drug and vehicle were injected daily
i.p. In A, the data for the six BQ788-treated mice were pooled. In B,
separate curves are drawn for the data from the three mice in which
BQ788 slowed tumor growth and for the data from the three mice in
which BQ788 caused the tumors to regress. P values were calculated
by using the Student’s t test and are indicated by p when significantly
different from controls (P , 0.05).
FIG. 8. TUNEL staining of A375 cell tumors grown in nude mice
reveals evidence for BQ788-stimulated apoptosis. Representative
sections are illustrated from four tumors from BQ788-injected (i.p.)
mice and three tumors from vehicle-injected mice. TUNEL-positive
cells are in most cases much more frequent in tumors from the
drug-treated animals, suggesting enhanced apoptosis. (A–D) BQ788-
treated mice. (A and B) Less-affected tumors. (C and D) Strongly
affected tumors. (E–G) Vehicle-treated mice. Pictures were taken at
320 magnification.
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S6c. Further evidence for a specific effect of BQ788 on
melanoma cells is its very different effect on kidney (293)
cells. Moreover, the ETRA selective blocker BQ123 does not
inhibit melanoma cell growth in culture, even at high con-
centration. Interestingly, the cell line with the highest degree
of sensitivity to BQ788 treatment, RPMI 7951, has the lowest
level of ETRB mRNA among the lines tested. Kikuchi et al.
(13) found that human metastatic melanoma cells display
decreased ETRB expression compared with primary mela-
noma cells, suggesting that metastatic melanoma cells could
be the most sensitive to treatment with BQ788.
The findings on cell viability in culture, particularly with
lines RPMI 7951, SK-MEL 28, and A375, as well as the
TUNEL results in vitro and in vivo, argue that BQ788 can
induce apoptosis. This is consistent with an autocriney
paracrine role for endothelins in melanoma survival and
growth (12, 14). Further support comes from our observation
that some of the melanoma lines express ET1 mRNA (data not
shown). In addition, the ETRB-specific agonist stimulates
growth of A375 cells (Fig. 5). The small but significant increase
in the number of viable cells that can be seen with the selective
ETRA antagonist BQ123 on A375 and SK-MEL 28 cells
argues that the A and B receptors mediate an entirely different
responses of endothelins on these cells. In the case of A375,
Ohtani et al. (14) found that whereas ETRB may mediate
proliferation, increased ETRA expression is associated with
differentiation and growth arrest (14), and, as shown in our
study, when ETRA is blocked, proliferation andyor survival
can be enhanced. In this respect it is interesting that Zhang et
al. (15) showed that the major ETRA transcript expressed by
several melanoma cell lines is truncated and does not bind ET
well.
Although it remains to be seen whether BQ788 is the most
effective ETRB antagonist for stopping melanoma growth in
vivo, there is evidence that such drugs can be well tolerated. In
an animal model of hypertension, BQ788 reduced renal blood
flow without affecting urine formation or causing toxic side
effects (21). In clinical trials, i.v. administration of 1,000 mg of
a nonselective ETR antagonist to healthy volunteers decreased
peripheral vascular resistance and blood pressure (22), and
another trial reported beneficial effects of another nonselec-
tive antagonist in patients with chronic heart failure (23).
Future experiments should address the question of why
systemic treatment with BQ788 results in slower tumor growth
for some animals while causing tumor regression in others. It
also will be important to test whether the effects are reversible
and whether ETRB antagonists also affect metastasis. Because
ETRA antagonists can reduce the growth of ovarian carci-
noma cells (24) and antagonize ET1-mediated proliferation of
prostate cancer cells (25) in culture, it will be worth testing ET
antagonists for treatment of these tumors as well.
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